"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at trametinib and pazopanib with paclitaxel for melanoma (PACMEL)
- had spread to nearby
lymph nodesor spread elsewhere in the body (advanced melanoma)
- couldn’t be removed with surgery
- cells didn’t have a change in the
More about this trial
Paclitaxel chemotherapy is a possible treatment for melanoma skin cancer that has spread. But it doesn’t always work very well.
Researchers are looking for ways to improve treatment for people with advanced melanoma. In this trial, they looked at 2 drugs called trametinib and pazopanib.
Doctors thought that adding trametinib or pazopanib to paclitaxel chemotherapy might work better than paclitaxel only. But they weren’t sure, so wanted to find out more.
The main aim of this trial was to find out if trametinib or pazopanib with paclitaxel chemotherapy improved treatment.
Summary of results
- 38 people had paclitaxel (group 1)
- 36 people had paclitaxel and trametinib (group 2)
- 37 people had paclitaxel and pazopanib (group 3)
- 13 out of every 100 people (13%) who had paclitaxel (group 1)
- 42 out of every 100 people (42%) who had paclitaxel and trametinib (group 2)
- 22 out of every 100 people (22%) who had paclitaxel and pazopanib (group 3)
The overall response rate showed that paclitaxel and trametinib worked best.
The researchers also looked at how long people lived after treatment. This is called overall survival. But they didn’t find any difference between the 3 groups.
- liver changes
- taste changes
How to join a clinical trial
Professor Mark Middleton
Cancer Research UK
University of Oxford